Ads
related to: rituxan for itp fda approved- View Prescribing Info
Click To Find Full Prescribing
Info For This Medication.
- About Chronic ITP
Learn More About What It Is
& How It Is Treated.
- Connect With Coordinators
Click To Download Our Forms
Or Get Assistance.
- Join For Exclusive Tips
Sign Up For Our Community Tips
Delivered To Your Doorstep & Inbox
- View Prescribing Info
Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
[32] [33] Romiplostim was approved by the United States Food and Drug Administration (FDA) for long-term treatment of adult chronic ITP on August 22, 2008. [ 34 ] Eltrombopag (trade name Promacta in the US, Revolade in the EU) is an orally-administered agent with an effect similar to that of romiplostim.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Rituxan (rituximab) is a type of antibody therapy (biologic) medication that may be used with or without chemotherapy. It destroys or helps your body destroy blood cells that contain cancer.
Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
The U.S. Food and Drug Administration (FDA) approved fostamatinib based on evidence from two identical, double-blind, placebo-controlled clinical trials, FIT-1 (NCT02076399) and FIT-2 (NCT02076412) of 150 adults with persistent or chronic ITP who had an insufficient response to previous treatment, which included corticosteroids, immunoglobulins ...
AbbVie's (ABBV) regulatory application seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan gets approval from the FDA.
Ads
related to: rituxan for itp fda approved